Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials
{{output}}
Objectives: Drug developers sometimes launch phase 3 (P3) trials without supporting evidence from phase 2 (P2) trials. We call this practice "P2 bypass." The aims of this study were to estimate the prevalence of P2 bypass and to ... ...
